Evidence map›Paper›PMID 39133676›Full record

ArticlePloS one2024

Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.

Giorgio Zenere, Chengxiang Wu, Cecily C Midkiff, Nathan M Johnson, Christopher P Grice, William C Wimley, Amitinder Kaur, Stephen E Braun

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Chimeric antigen receptor therapies: Development, design, and implementation.The Journal of allergy and clinical immunology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Giorgio ZenereTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, United States of America.
Chengxiang WuTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, United States of America.
Cecily C MidkiffTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, United States of America.
Nathan M JohnsonTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, United States of America.
Christopher P GriceTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, United States of America.
William C WimleyDepartment of BioChemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana, United States of America.ORCID 0000-0003-2967-5186
Amitinder KaurTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, United States of America.
Stephen E BraunTulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, United States of America.ORCID 0000-0002-4521-2678

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
NKT cells as modulators of AIDS vaccine efficacyR01AI102693 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUR, AMITINDER · 2012 to 2015
$3.2M
High Throughput Multicolor Flow Cytometer Cell AnalyzerS10OD026800 · OD · TULANE UNIVERSITY OF LOUISIANA · PI KAUR, AMITINDER · 2019 to 2019
$594k
Genetically Modified NKT Cells to Target Viral ReservoirsR21AI145642 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI BRAUN, STEPHEN EDWARD, KAUR, AMITINDER · 2019 to 2020
$468k
Modifying CMV-specificT cells with a novel bicistronic CD4-CAR/maC46 vector to target HIVF30AI150452 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI JOHNSON, NATHAN MICHEL · 2019 to 2021
$152k
NIAID NIH HHS F30 AI150452NIAID NIH HHS R01 AI102693NIAID NIH HHS R21 AI145642NIH HHS AL110158NIH HHS P51 OD011104NIH HHS S10 OD026800
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-T cells have demonstrated clinical potential, but current receptors still need improvements to be successful against chronic HIV infection. In this study, we address some requirements of CAR motifs for strong surface expression of a novel anti-HIV CAR by evaluating important elements in the extracellular, hinge, and transmembrane (TM) domains. When combining a truncated CD4 extracellular domain and CD8α hinge/TM, the novel CAR did not express extracellularly but was detectable intracellularly. By shortening the CD8α hinge, CD4-CAR surface expression was partially recovered and addition of the LYC motif at the end of the CD8α TM fully recovered both intracellular and extracellular CAR expression. Mutation of LYC to TTA or TTC showed severe abrogation of CAR expression by flow cytometry and confocal microscopy. Additionally, we determined that CD4-CAR surface expression could be maximized by the removal of FQKAS motif at the junction of the extracellular domain and the hinge region. CD4-CAR surface expression also resulted in cytotoxic CAR T cell killing of HIV Env+ target cells. In this study, we identified elements that are crucial for optimal CAR surface expression, highlighting the need for structural analysis studies to establish fundamental guidelines of CAR designs.

Indexed as

CD4 AntigensReceptors, Chimeric AntigenAmino Acid MotifsCD8 AntigensCell MembraneHEK293 CellsHIV-1HIV InfectionsHumansProtein DomainsCD4 AntigensCD8 AntigensReceptors, Chimeric Antigen

Identifiers

PMID39133676
PMCPMC11318886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.